-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on AbbVie, Maintains $280 Price Target

Benzinga·10/13/2026 14:22:06
RBC Capital analyst Trung Huynh reiterates AbbVie (NYSE:ABBV) with a Outperform and maintains $280 price target.